A week after the maker of a controversial Alzheimer's drug announced it would largely stop marketing it, Congress is readying legislation that tinkers with the pathway used by the FDA to approve the drug, but avoids making large-scale changes.Aduhelm's approval created heightened scrutiny around whether the FDA's "accelerated approval" process is being used appropriately. But as the drug fades largely into the background, so are the calls for stringent reforms.
But the process has drawn concern because of the way it could put big-ticket drugs in the public's hands that may wind up being ineffective or unsafe. The bipartisan legislation also clarifies conditions under which the FDA could withdraw an accelerated approval and adds labeling requirements for drugs that go through the process.Democrats and Republicans were divided over how far to go, with Democrats in favor of putting more of the onus on manufacturers to justify keeping the approvals and Republicans wanting to expand the use of the pathway, per Cowen analysts Eric Assaraf and Rick Weissenstein.
yeah let me sell you a sugar pill to my patients who cannot remember if it works or not lol
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Eater - 🏆 368. / 59 Read more »
Source: POPSUGAR Fitness - 🏆 401. / 53 Read more »
Source: ABC7NY - 🏆 592. / 51 Read more »
Source: ChicagoBreaking - 🏆 521. / 51 Read more »
Source: PsychToday - 🏆 714. / 51 Read more »
Source: etnow - 🏆 696. / 51 Read more »